Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 10:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 8,242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Humans Clear all
Not listed Phase 1 Interventional

Dose Finding Study of L19TNF and Doxorubicin in Patients With STS

NCT04032964
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
L19TNF, DOXORUBICIN
Drug
Lead sponsor
Philogen S.p.A.
Industry
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 25, 2026, 10:04 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis

NCT00999609
View directory record Official record
Conditions
Inherited Retinal Dystrophy Due to RPE65 Mutations, Leber Congenital Amaurosis
Interventions
AAV2-hRPE65v2,voretigene neparvovec-rzyl
Biological
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
2
States / cities
Iowa City, Iowa • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 25, 2026, 10:04 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects

NCT01499199
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Dolutegravir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 25, 2015 · Synced Oct 25, 2026, 10:04 AM EDT
Recruiting Phase 2 Interventional

Human Craniomaxillofacial Allotransplantation

NCT01889381
View directory record Official record
Conditions
Facial Injuries, Traumatic Wounds and Injuries, Craniofacial Injuries, Craniofacial Defects, Facial Transplantation, Facial Deformity
Interventions
Bone marrow cell-based therapy & 1-drug immunosuppression.
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2041
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 25, 2026, 10:04 AM EDT
Recruiting Phase 1 Interventional

Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants

NCT07673900
View directory record Official record
Conditions
Overweight and/or Obesity
Interventions
VX-201, semaglutide SC
Combination Product · Drug
Lead sponsor
Terrestrial Bio, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 25, 2026, 10:04 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds

NCT02120755
View directory record Official record
Conditions
Diabetic Foot Ulcers, Wound Care
Interventions
AmnioClear™ Human Allograft Amniotic Membrane
Biological
Lead sponsor
Liventa Bioscience
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Oct 25, 2026, 10:04 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants

NCT01215643
View directory record Official record
Conditions
Hepatitis C, Chronic Pain
Interventions
Alisporivir, Peginterferon alfa-2a, Ribavirin
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
16
States / cities
La Jolla, California • San Diego, California • Ventura, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 25, 2026, 10:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Epigenetic Effects of Diesel Exhaust and Ozone Exposure

NCT01492517
View directory record Official record
Conditions
Exposure to Pollution, Inhalation of Ozone
Interventions
Ozone exposure, Diesel exhaust, Ozone18, Clean Air
Other
Lead sponsor
Environmental Protection Agency (EPA)
Federal
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 25, 2026, 10:04 AM EDT
Completed Not applicable Interventional

Adult Influenza Vaccination Text Message Reminders

NCT01942824
View directory record Official record
Conditions
Influenza Vaccination
Interventions
Text Messages
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
7,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 25, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional Results available

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

NCT00718523
View directory record Official record
Conditions
Ovarian Neoplasms
Interventions
AMG 479, AMG 479 Placebo
Drug
Lead sponsor
Translational Research in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
23
States / cities
Alhambra, California • Burbank, California • Fullerton, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 25, 2026, 10:04 AM EDT
Active, not recruiting Not applicable Interventional

Buprenorphine Integration Research and Community Health

NCT05668780
View directory record Official record
Conditions
Opioid Use Disorder, HIV Infections, Hepatitis C
Interventions
NIATx Coaching
Behavioral
Lead sponsor
Yale University
Other
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 25, 2026, 10:04 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV

NCT00001281
View directory record Official record
Conditions
HIV, Immunodeficiencies, Infectious Diseases
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 120 Years
Enrollment
2,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1993
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 25, 2026, 10:04 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of AC607 for the Treatment of Kidney Injury in Cardiac Surgery Subjects

NCT01602328
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
AC607, Vehicle Only
Biological
Lead sponsor
AlloCure Inc.
Industry
Eligibility
21 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • San Diego, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 25, 2026, 10:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.

NCT00549211
View directory record Official record
Conditions
Obstetric Labour, Premature, Premature Ejaculation
Interventions
GSK557296
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 19, 2012 · Synced Oct 25, 2026, 10:04 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study

NCT01133509
View directory record Official record
Conditions
Genital Human Papilloma Virus Infection
Interventions
Gardasil
Drug
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
18 Years to 26 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 25, 2026, 10:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of PMT Therapy of hPAP

NCT05761899
View directory record Official record
Conditions
Hereditary Pulmonary Alveolar Proteinosis
Interventions
Gene-Corrected Macrophages administered by bronchoscopic instillation
Combination Product
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 25, 2026, 10:04 AM EDT
Recruiting Phase 1 Interventional

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

NCT05877599
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS)
Interventions
NT-175
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
20
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 10:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Acute Effects of Coffee on Glucose Metabolism

NCT00950898
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
decaff, caffcoff, caffeine, placebo
Other
Lead sponsor
Brooklyn College of the City University of New York
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2009 · Synced Oct 25, 2026, 10:04 AM EDT
Withdrawn Phase 2 Interventional

Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates

NCT05404919
View directory record Official record
Conditions
Lung Transplant, Hepatitis B
Interventions
Hepatitis B Immune Globulin and entecavir, tenofovir disoproxil, or tenofovir alafenamide
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 25, 2026, 10:04 AM EDT
Completed Phase 2 Interventional

Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer

NCT00968630
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection
Interventions
Laboratory Biomarker Analysis, Leukapheresis
Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Oct 25, 2026, 10:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SaliPen Human Factors Study for OTC Labeling

NCT05058430
View directory record Official record
Conditions
Xerostomia
Interventions
Electrical salivary stimulator system assigned to subjects with xerostomia, No Electrical salivary stimulator system assigned to subjects without xerostomia
Device
Lead sponsor
Saliwell Ltd.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Oct 25, 2026, 10:04 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Finger Muscle Reaction After Electrical Stimuli to the Human Finger Pulley System; a Pilot Study

NCT01456871
View directory record Official record
Conditions
Healthy
Interventions
Guided insertion of electrodes, Electromyographic (EMG) recording
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years to 30 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 25, 2026, 10:04 AM EDT
Completed Phase 3 Interventional

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

NCT00295763
View directory record Official record
Conditions
Differentiated Thyroid Cancer
Interventions
Thyrogen (thyrotropin alfa for injection)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
4
States / cities
Aurora, Colorado • Baltimore, Maryland • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 25, 2026, 10:04 AM EDT
Completed Phase 4 Interventional

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

NCT02882100
View directory record Official record
Conditions
Influenza, Influenza-like Illness
Interventions
adjuvanted trivalent influenza vaccine, trivalent influenza vaccine
Biological
Lead sponsor
Insight Therapeutics, LLC
Other
Eligibility
65 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 25, 2026, 10:04 AM EDT